Year | Title | Author(s) |
2013 |
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
Scientific Reports |
Miles, LA Crespi, GAN Doughty, L Parker, MW |
2014 |
Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-beta
Acta Crystallographica Section F-structural Biology And Crystallization Communications |
Crespi, GAN Ascher, DB Parker, MW Miles, LA |
2014 |
Do current therapeutic anti-A beta antibodies for Alzheimer's disease engage the target?
Acta Neuropathologica |
Watt, AD Crespi, GAN Down, RA Ascher, DB Gunn, A Perez, KA McLean, CA Villemagne, VL Parker, MW Barnham, KJ Miles, LA |
2014 |
Anti-A beta antibody target engagement: a response to Siemers et al.
Acta Neuropathologica |
Watt, AD Crespi, GAN Down, RA Ascher, DB Gunn, A Perez, KA McLean, CA Villemagne, VL Parker, MW Barnham, KJ Miles, LA |
2015 |
Molecular basis for mid-region amyloid-beta capture by leading Alzheimer's disease immunotherapies
Scientific Reports |
Crespi, GAN Hermans, SJ Parker, MW Miles, LA |
2015 |
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
Acta Neuropathol. |
Bouter, Y Noguerola, JSL Tucholla, P Crespi, GAN Parker, MW Wiltfang, J Miles, LA Bayer, TA |
2017 |
Ex vivo O-18-labeling mass spectrometry identifies a peripheral amyloid beta clearance pathway
Mol. Neurodegener. |
Portelius, E Mattsson, N Pannee, J Zetterberg, H Gisslen, M Vanderstichele, H Gkanatsiou, E Crespi, GAN Parker, MW Miles, LA Gobom, J Blennow, K |
2019 |
Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes A beta Phagocytosis
Iscience |
Miles, LA Hermans, SJ Crespi, GAN Gooi, JH Doughty, L Nero, TL Markulic, J Ebneth, A Wroblowski, B Oehlrich, D Trabanco, AA Rives, ML Royaux, I Hancock, NC Parker, MW |